fluorouracil has been researched along with Epiphora in 10 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the prevalence of tearing and canalicular fibrosis in patients receiving systemic 5-fluorouracil (5-FU) therapy and the reversibility of the symptoms when treatment is stopped." | 7.70 | Epiphora in patients receiving systemic 5-fluorouracil therapy. ( Burkes, RL; Hassan, A; Hurwitz, JJ, 1998) |
| " Ocular discomfort occurred in 43 of 49 patients in the fluorouracil group versus 36 of 49 in the placebo group, epiphora occurred in 24 versus five, and eyelid skin inflammation occurred in seven versus none." | 5.22 | Topical fluorouracil after surgery for ocular surface squamous neoplasia in Kenya: a randomised, double-blind, placebo-controlled trial. ( Burton, MJ; Gichuhi, S; Kabiru, J; Macharia, E; Maina, J; Munene, R; Ollando, E; Onyuma, T; Rono, H; Sagoo, MS; Wachira, J; Weiss, HA; Zindamoyen, AM, 2016) |
| " When the total dose of 5-fluorouracil reached 21,200 mg and the total dose of oxaliplatin reached 880 mg after about 100 days of treatment, epiphora developed." | 3.74 | [Epiphora in a patient receiving FOLFOX therapy]. ( Iwagami, E; Niimi, M; Ono, Y; Tanaka, E; Uto, N; Yamato, M; Yatsuda, C, 2008) |
| "To determine the prevalence of tearing and canalicular fibrosis in patients receiving systemic 5-fluorouracil (5-FU) therapy and the reversibility of the symptoms when treatment is stopped." | 3.70 | Epiphora in patients receiving systemic 5-fluorouracil therapy. ( Burkes, RL; Hassan, A; Hurwitz, JJ, 1998) |
| "5-Fluorouracil (5-FU) has been reported to cause punctal-canalicular fibrosis with resultant severe epiphora." | 3.67 | Surgical treatment of punctal-canalicular fibrosis from 5-fluorouracil therapy. ( Adams, T; Seiff, SR; Shorr, N, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (50.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Polski, A | 1 |
| Sibug Saber, M | 1 |
| Kim, JW | 1 |
| Berry, JL | 1 |
| Gichuhi, S | 1 |
| Macharia, E | 1 |
| Kabiru, J | 1 |
| Zindamoyen, AM | 1 |
| Rono, H | 1 |
| Ollando, E | 1 |
| Wachira, J | 1 |
| Munene, R | 1 |
| Maina, J | 1 |
| Onyuma, T | 1 |
| Sagoo, MS | 1 |
| Weiss, HA | 1 |
| Burton, MJ | 1 |
| Yatsuda, C | 1 |
| Niimi, M | 1 |
| Ono, Y | 1 |
| Uto, N | 1 |
| Iwagami, E | 1 |
| Tanaka, E | 1 |
| Yamato, M | 1 |
| Eiseman, AS | 1 |
| Flanagan, JC | 1 |
| Brooks, AB | 1 |
| Mitchell, EP | 1 |
| Pemberton, CH | 1 |
| Reny, A | 1 |
| George, JL | 1 |
| Hassan, A | 1 |
| Hurwitz, JJ | 1 |
| Burkes, RL | 1 |
| Christophidis, N | 2 |
| Vajda, FJ | 2 |
| Lucas, I | 2 |
| Louis, WJ | 2 |
| Haidak, DJ | 1 |
| Hurwitz, BS | 1 |
| Yeung, KY | 1 |
| Seiff, SR | 1 |
| Shorr, N | 1 |
| Adams, T | 1 |
1 review available for fluorouracil and Epiphora
| Article | Year |
|---|---|
[Iatrogenic lacrimal pathology].
Topics: Adrenergic beta-Antagonists; Anesthetics; Antiviral Agents; Epinephrine; Fluorouracil; Histamine H1 | 1982 |
1 trial available for fluorouracil and Epiphora
| Article | Year |
|---|---|
Topical fluorouracil after surgery for ocular surface squamous neoplasia in Kenya: a randomised, double-blind, placebo-controlled trial.
Topics: Administration, Topical; Adult; Antimetabolites, Antineoplastic; Carcinoma; Double-Blind Method; Eye | 2016 |
8 other studies available for fluorouracil and Epiphora
| Article | Year |
|---|---|
Extending far and wide: the role of biopsy and staging in the management of ocular surface squamous neoplasia.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Squamous Cell; Conjunctival Neoplasms; Corneal Disea | 2019 |
[Epiphora in a patient receiving FOLFOX therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Lacrimal Apparatus Disea | 2008 |
Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil.
Topics: Adult; Antimetabolites, Antineoplastic; Black or African American; Cohort Studies; Drug Eruptions; E | 2003 |
Epiphora in patients receiving systemic 5-fluorouracil therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fib | 1998 |
Ocular side effects with 5-fluorouracil.
Topics: Chromatography, Gas; Fluorouracil; Humans; Lacrimal Apparatus; Lacrimal Apparatus Diseases; Tears | 1979 |
Tear-duct fibrosis (dacryostenosis) due to 5-fluorouracil.
Topics: Breast Neoplasms; Colonic Neoplasms; Fluorouracil; Humans; Lacrimal Apparatus Diseases | 1978 |
Lacrimation and 5-fluorouracil.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Lacrimal Apparatus Diseases; Tears | 1978 |
Surgical treatment of punctal-canalicular fibrosis from 5-fluorouracil therapy.
Topics: Aged; Conjunctiva; Dacryocystorhinostomy; Female; Fluorouracil; Humans; Lacrimal Apparatus Diseases; | 1985 |